Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 2011. The report serves as a notification of transactions involving a Director, specifically Mr. A P Witty, in accordance with Disclosure Rule 3.1.4R(1)(a).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of a specific director's share transaction rather than a financial performance report.
Material Changes
The filing details a specific transaction on November 4, 2011, involving Mr. A P Witty:
- Exercise of options over 72,000 Ordinary shares granted on December 3, 2002, at an exercise price of £11.79 per share.
- Sale of 67,213 Ordinary shares on the same date at a price of £13.78 per share.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items beyond the disclosed director transaction.
Investor Verification Points
- Verify the total number of shares held by Mr. A P Witty following the exercise and sale.
- Confirm the timing of the transaction relative to any material non-public information.
- Review the terms of the GlaxoSmithKline Share Option Plan under which the options were granted.